- Home
- JYD vs IMNN Comparison
JYD vs IMNN Comparison
Compare JYD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | IMNN |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 11.0M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | JYD | IMNN |
|---|---|---|
| Price | $2.95 | $2.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 42.0K | 18.1K |
| Earning Date | 10-15-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.37 |
| 52 Week High | $8.00 | $9.32 |
Technical Indicators
Market Signals| Indicator | JYD | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 36.96 |
| Support Level | $2.42 | $0.48 |
| Resistance Level | $3.01 | $3.16 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 76.23 | 7.79 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).